EGFR and non-small cell lung carcinoma: In conclusion, this report describes a patient with EGFR-mutant NSCLC small-cell type transformation and gastric metastasis after osimertinib treatment, suggesting the necessity of another biopsy because of the non-classical metastasis in the stomach.